According to the new research report published by Precedence Research, titled “Cell and Gene Therapy Market (By Therapy Type: Cell Therapy and Gene Therapy; By Indication: Cardiovascular Disease, Cancer, Genetic Disorders, Infectious Diseases, Neurological Disorders; By Delivery Method: In-Vivo and Ex-vivo; By End-Users: Hospitals, Cancer Care Centers, Wound Care Centers, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030 (By Product: Traditional, Advanced; By Application: Pottery, Tiles, Abrasives, Sanitary wave, Bricks & pipes, Others; By End User: Medical, Industrial, Building & Construction, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030”, the global cell and gene therapy market size is expected to be worth around US$ 93.78 billion by 2030 and is poised to record a yearly growth rate of 22.41% from 2022 to 2030. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on cell and gene therapy market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall cell and gene therapy market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2445
The study also provides important advancements in organic and inorganic growth strategies in the worldwide cell and gene therapy market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of cell and gene therapy market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Cell and Gene Therapy Market Report Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 18.61 Billion |
| Market Size by 2030 | USD 93.78 Billion |
| CAGR | 22.41% From 2022 to 2030 |
| Gene Therapy Segment Market Share | 52% in 2022 |
| North America Market Share | 48% in 2022 |
| Base Year | 2022 |
Also read: LED Driver Market Size to Worth US$ 34.85 Billion by 2030
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the cell and gene therapy market.
Some of the prominent players in the cell and gene therapy market include
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Biogen Inc.
- CORESTEM Inc.
- Dendreon Pharmaceuticals LLC.
- Helixmith Co. Ltd.
- JCR Pharmaceuticals Co. Ltd.
- Kolon TissueGene Inc.
- Novartis AG
- Pfizer Inc.
Cell and Gene Therapy Market Segmentations
By Therapy Type
- Cell Therapy
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
- Tumor Cells
- Gene Therapy
By Therapeutic class
- Cardiovascular Disease
- Cancer
- Genetic Disorder
- Rare Diseases
- Oncology
- Hematology
- Ophthalmology
- Infectious Disease
- Neurological Disorders
By Delivery Method
- In Vivo
- Ex vivo
By End-Users
- Hospitals
- Cancer Care Centers
- Wound Care Centers
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Report Objectives
- To define, segment, and project the global market size for cell and gene therapy market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyse the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyse their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyse the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cell and Gene Therapy Market
5.1. COVID-19 Landscape: Cell and Gene Therapy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cell and Gene Therapy Market, By Therapy Type
8.1. Cell and Gene Therapy Market, by Therapy Type, 2022-2030
8.1.1. Cell Therapy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Gene Therapy
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cell and Gene Therapy Market, By Therapeutic class
9.1. Cell and Gene Therapy Market, by Therapeutic class, 2022-2030
9.1.1. Cardiovascular Disease
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Cancer
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Genetic Disorder
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Rare Diseases
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Oncology
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Oncology
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Ophthalmology
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Infectious Disease
9.1.8.1. Market Revenue and Forecast (2017-2030)
9.1.9. Neurological Disorders
9.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cell and Gene Therapy Market, By Delivery Method
10.1. Cell and Gene Therapy Market, by Delivery Method, 2022-2030
10.1.1. In Vivo
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Ex vivo
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cell and Gene Therapy Market, By End-Users
11.1. Cell and Gene Therapy Market, by End-Users, 2022-2030
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cancer Care Centers
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Wound Care Centers
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Cell and Gene Therapy Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.1.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.1.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.1.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.1.5.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.1.6.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.2.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.2.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.2.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.2.5.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.2.6.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.2.7.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.2.8.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.3.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.3.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.3.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.3.5.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.3.6.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.3.7.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.3.8.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.4.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.4.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.4.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.4.5.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.4.6.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.4.7.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.4.8.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.5.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.5.5.4. Market Revenue and Forecast, by End-Users (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Therapeutic class (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Delivery Method (2017-2030)
12.5.6.4. Market Revenue and Forecast, by End-Users (2017-2030)
Chapter 13. Company Profiles
13.1. Alnylam Pharmaceuticals Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amgen Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Biogen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. CORESTEM Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Dendreon Pharmaceuticals LLC.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Helixmith Co. Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. JCR Pharmaceuticals Co. Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Kolon TissueGene Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global cell and gene therapy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cell and gene therapy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
